TY - JOUR
T1 - Deconvolution analysis of spontaneous nocturnal growth hormone secretion in prepubertal children with preterminal chronic renal failure and with end-stage renal disease
AU - Tonshoff, Burkhard
AU - Veldhuis, Johannes D.
AU - Heinrich, Udo
AU - Mehls, Otto
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1995/1
Y1 - 1995/1
N2 - We sought to determine whether elevated circulating growth hormone (GH) concentrations in uremic prepubertal children are due to an increase in GH secretory activity by the pituitary gland or a decrease in the metabolic clearance of GH consequent to reduced GFR. Deconvolution analysis was applied to the nighttime plasma GH profiles of i) 11 children with preterminal chronic renal failure, 2) 12 children with end-stage renal disease (ESRD), and 3) a control group of matched children with idiopathic short stature (n = 12). Mean (± SEM) half-life of endogenous GH in children with ESRD (27.5 ± 2.7 min) and preterminal chronic renal failure (23.1 ±2.1 min) was significantly higher than in controls (14.8 ± 1.6 min; p < 0.001). GH half-life correlated inversely with GFR (r = -0.65, p < 0.001). The number of GH secretory bursts/10 h in ESRD (8.1 ± 0.4) was amplified compared with preterminal chronic renal failure (6.4 ± 0.5) and with controls (5.9 ± 0.4; p < 0.005). GH production rate varied over a broad range in the three groups: It was highest in ESRD (202 ± 56.6 mg/L/10 h; range 36-683), mainly as a result of an increased number of GH secretory bursts, and not statistically different in preterminal chronic renal failure (66.2 ± 11.4 mg/L/10 h; range 25-168) and in controls (129 ± 27.7 mg/L/10 h; range 39-392). Increased GH half-life, in concert with an increased GH production in some individuals with ESRD, leads to a 2.5-fold increase in the mean plasma GH concentration in ESRD compared with the two other groups (p < 0.005). However, total immunoreactive plasma IGF-I levels were indistinguishable between groups. This disruption of the normal relationship between circulating GH and total plasma IGF-I levels in ESRD suggests a relative insensitivity to the action of GH in uremia, at least in those target organs (e.g. liver) that contribute predominantly to circulating IGF-I levels.
AB - We sought to determine whether elevated circulating growth hormone (GH) concentrations in uremic prepubertal children are due to an increase in GH secretory activity by the pituitary gland or a decrease in the metabolic clearance of GH consequent to reduced GFR. Deconvolution analysis was applied to the nighttime plasma GH profiles of i) 11 children with preterminal chronic renal failure, 2) 12 children with end-stage renal disease (ESRD), and 3) a control group of matched children with idiopathic short stature (n = 12). Mean (± SEM) half-life of endogenous GH in children with ESRD (27.5 ± 2.7 min) and preterminal chronic renal failure (23.1 ±2.1 min) was significantly higher than in controls (14.8 ± 1.6 min; p < 0.001). GH half-life correlated inversely with GFR (r = -0.65, p < 0.001). The number of GH secretory bursts/10 h in ESRD (8.1 ± 0.4) was amplified compared with preterminal chronic renal failure (6.4 ± 0.5) and with controls (5.9 ± 0.4; p < 0.005). GH production rate varied over a broad range in the three groups: It was highest in ESRD (202 ± 56.6 mg/L/10 h; range 36-683), mainly as a result of an increased number of GH secretory bursts, and not statistically different in preterminal chronic renal failure (66.2 ± 11.4 mg/L/10 h; range 25-168) and in controls (129 ± 27.7 mg/L/10 h; range 39-392). Increased GH half-life, in concert with an increased GH production in some individuals with ESRD, leads to a 2.5-fold increase in the mean plasma GH concentration in ESRD compared with the two other groups (p < 0.005). However, total immunoreactive plasma IGF-I levels were indistinguishable between groups. This disruption of the normal relationship between circulating GH and total plasma IGF-I levels in ESRD suggests a relative insensitivity to the action of GH in uremia, at least in those target organs (e.g. liver) that contribute predominantly to circulating IGF-I levels.
UR - http://www.scopus.com/inward/record.url?scp=0028876890&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028876890&partnerID=8YFLogxK
U2 - 10.1203/00006450-199501000-00017
DO - 10.1203/00006450-199501000-00017
M3 - Article
C2 - 7700739
AN - SCOPUS:0028876890
SN - 0031-3998
VL - 37
SP - 86
EP - 93
JO - Pediatric Research
JF - Pediatric Research
IS - 1
ER -